BMS submitted LAG-3+PD-1 fixed-dose compound market application and received FDA priority review

Article source: Medical Rubik's Cube Info

On September 20, BMS announced that the FDA has accepted the marketing application of relatlimab (LAG-3) + nivolumab (PD-1) fixed-dose combination combination for the treatment of unresectable or unresectable or non-resectable or For metastatic melanoma, PDUFA's scheduled approval period is March 19, 2022
.

Lymphocyte activation gene-3 (LAG-3) and programmed death receptor-1 (PD-1) are two different inhibitory immune checkpoints, usually co-expressed in tumor-infiltrating lymphocytes (TILs) and cause tumors Mediated T cell failure
.

On May 19 this year, BMS published the clinical trial data of Phase II/III RELATIVITY-047 study
.

The safety of the fixed-dose combination therapy of Relatlimab and Opdivo is controllable, consistent with the previously reported situation
.

If the combination therapy is approved, relatlimab will be the third type of immune checkpoint inhibitor listed after CTLA4 and PD1-1/PD-L1